传统的心身炼对神经退行性疾病或前兆性认知衰退中的认知功能的影响:一个元分析
Xin Liu1,2, Cai Cui2, Jiacan Lv3
1College of Physical Education, Yangzhou University, Yangzhou, China.
Frontiers in public health
|February 27, 2026
概括
传统的心身炼显著改善了神经退行性疾病 (NDD) 和前兆性认知衰退患者的认知功能. 这些安全的非药物干预措施为管理认知障碍提供了一个有希望的方法.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 康复医学 康复医学 康复医学
背景情况:
- 神经退行性疾病 (NDD) 和突发性认知衰退对认知功能构成重大挑战.
- 太极拳和等传统的心身炼 (TMBE) 越来越多地被探索其潜在的治疗益处.
- 需要进行系统的评估,以评估TMBE对风险人群认知健康的有效性.
研究的目的:
- 系统地评估TMBE对患有NDD或前发性认知衰退的患者认知功能的影响.
- 综合来自随机对照试验 (RCT) 关于TMBE干预措施有效性的证据.
主要方法:
- 在主要数据库 (PubMed,Cochrane,Web of Science,Embase) 进行了全面的文献搜索,搜索到2025年10月发布的RCT.
- 该研究包括患有阿尔茨海默病 (AD),帕金森病 (PD),轻度认知障碍 (MCI) 或主观认知衰退 (SCD) 的成年参与者.
- 用随机效应模型分析数据,通过MMSE,MoCA和其他特定的认知测试评估认知功能;使用Cochrane风险偏差工具评估研究质量.
主要成果:
- 涉及TMBE干预的21个RCT显示,通过MMSE和MoCA得分测量,整体认知功能显著改善.
- TMBE对特定的认知领域产生了积极的影响,包括执行功能,语言流性和延迟回忆,特别是在轻度痴呆症患者中.
- 虽然注意力改善总体上是积极的,但结果因评估工具而异;异质性通过敏感性分析得到解决,发现出版偏差很低.
结论:
- 在患有NDD或前发性认知衰退的个体中,TMBE干预措施在增强整体和特定认知功能方面表现出显著的有效性.
- 这些练习代表了一种安全,可靠和多目标的非药物战略,用于改善这一群体的认知障碍.
- 这些发现支持将TMBE纳入认知衰退和神经退行性疾病的管理计划.
更多相关视频
相关概念视频
Cognitive Development During Adulthood
988
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
988
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
735
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
735
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K


